Form 4: Elicio Therapeutics Director Carol Ashe Acquires Stock Options

Director Carol Ashe reports acquisition of stock options in Elicio Therapeutics.

Summary

• Carol Ashe, a director of Elicio Therapeutics, filed a Form 4 indicating a transaction involving derivative securities.
• On May 19, 2025, Ashe acquired stock options representing the right to buy 7,900 shares of Elicio Therapeutics common stock at an exercise price of $5.84.
• The options vest fully on the earlier of May 19, 2026, or the next annual meeting of the company's stockholders after the grant date, contingent upon continued service to the issuer.
• Following the reported transaction, Ashe directly owns 7,900 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, transact in their company's securities. This filing indicates a grant of stock options to a director, which is a common form of executive compensation.

Stakeholder Impact

• The granting of stock options to a director aligns their interests with those of shareholders, potentially incentivizing them to work towards increasing the company's value.

Key Dates

Keywords

Form 4, Elicio Therapeutics, Stock Options, Carol Ashe, Director, ELTX, Beneficial Ownership, Derivative Securities